Add group to favorites
Back to post list
Send new message to group Search:
Post Subject:
Age-related macular degeneration nutritional supplement
Age-related macular degeneration nutritional supplement
TOZAL Study: An open case control study of an oral antioxidant and
omega-3 supplement for dry AMD
Francis E Cangemi
BMC Ophthalmology 2007, 7:3 doi:10.1186/1471-2415-7-3
Published 26 February 2007
Abstract (provisional)
Background
The primary objective of this prospective study was to measure the
change from baseline in visual function - Best-Corrected Visual Acuity
(BCVA) via the Early Treatment Diabetic Retinopathy Study (ETDRS)
chart, contrast sensitivity, central 10 degree visual fields and
retinal imaging (angiograms and photographs) at 6 months in subjects
with atrophic (dry) age-related macular degeneration treated with a
targeted nutritional supplement.
Methods
37 mixed gender patients with a mean age of 76.3 +/- 7.8 years were
enrolled at 5 independent study sites and received standard of care
with a novel formulation of a nutritional supplement. Results were
compared to a placebo cohort constructed from the literature that was
matched for inclusion and exclusion criteria. A paired t-test was used
to test a null hypothesis and a two-sided alpha level of 0.05 was used
to determine statistical significance.
Results
76.7% of subjects receiving the nutritional supplement demonstrated
stabilization or improvement of BCVA at 6 months. Subjects gained an
average of 0.0541 logMAR or one-half of a line of visual acuity (VA)
over the 6-month period. There was a statistically significant
improvement in VA from baseline with P = .045. The results provide
strong evidence that the treatment being studied produces an
improvement in VA.
Conclusions
Treatment with this unique nutritional supplement increased VA above
the expected baseline decrease in the majority of patients in this
population with dry macular degeneration. The results of the TOZAL
study agree with the LAST and CARMIS studies and are predictive for
positive visual acuity outcomes in the AREDS II trial. However,
patients will likely require supplementation for longer than 6 months
to effect changes in additional visual parameters. Trial Registration
The study is registered with the International Standard Randomised
Controlled Trial Register and the trial registration number is
ISRCTN57556290.
Who loves ya.
Tom
Jesus Was A Vegetarian!
* jesuswasavegetarian.7h . com
Man Is A Herbivore!
* tinyurl . com /a3cc3
DEAD PEOPLE WALKING
* tinyurl . com /zk9fk
TOZAL Study: An open case control study of an oral antioxidant and
omega-3 supplement for dry AMD
Francis E Cangemi
BMC Ophthalmology 2007, 7:3 doi:10.1186/1471-2415-7-3
Published 26 February 2007
Abstract (provisional)
Background
The primary objective of this prospective study was to measure the
change from baseline in visual function - Best-Corrected Visual Acuity
(BCVA) via the Early Treatment Diabetic Retinopathy Study (ETDRS)
chart, contrast sensitivity, central 10 degree visual fields and
retinal imaging (angiograms and photographs) at 6 months in subjects
with atrophic (dry) age-related macular degeneration treated with a
targeted nutritional supplement.
Methods
37 mixed gender patients with a mean age of 76.3 +/- 7.8 years were
enrolled at 5 independent study sites and received standard of care
with a novel formulation of a nutritional supplement. Results were
compared to a placebo cohort constructed from the literature that was
matched for inclusion and exclusion criteria. A paired t-test was used
to test a null hypothesis and a two-sided alpha level of 0.05 was used
to determine statistical significance.
Results
76.7% of subjects receiving the nutritional supplement demonstrated
stabilization or improvement of BCVA at 6 months. Subjects gained an
average of 0.0541 logMAR or one-half of a line of visual acuity (VA)
over the 6-month period. There was a statistically significant
improvement in VA from baseline with P = .045. The results provide
strong evidence that the treatment being studied produces an
improvement in VA.
Conclusions
Treatment with this unique nutritional supplement increased VA above
the expected baseline decrease in the majority of patients in this
population with dry macular degeneration. The results of the TOZAL
study agree with the LAST and CARMIS studies and are predictive for
positive visual acuity outcomes in the AREDS II trial. However,
patients will likely require supplementation for longer than 6 months
to effect changes in additional visual parameters. Trial Registration
The study is registered with the International Standard Randomised
Controlled Trial Register and the trial registration number is
ISRCTN57556290.
Who loves ya.
Tom
Jesus Was A Vegetarian!
* jesuswasavegetarian.7h . com
Man Is A Herbivore!
* tinyurl . com /a3cc3
DEAD PEOPLE WALKING
* tinyurl . com /zk9fk
Re: Age-related macular degeneration nutritional supplement
One half of a line of visual acuity improvement is well within the
standard deviation of the reading of the ETDRS or the Snellen chart.
I would bet.
Don W
One half of a line of visual acuity improvement is well within the
standard deviation of the reading of the ETDRS or the Snellen chart.
I would bet.
Don W
